Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LabCorp Begins Offering Exact Sciences’ PreGen-Plus Colorectal Cancer Test

This article was originally published in The Gray Sheet

Executive Summary

Exact Sciences hopes consultation with FDA on clinical utility trials for the firm's PreGen-Plus colorectal cancer screening assay will help fulfill potential regulatory requirements in the future
Advertisement

Related Content

FDA May Require Premarket Clearance For Exact Sciences’ PreGen-Plus
FDA May Require Premarket Clearance For Exact Sciences’ PreGen-Plus
Multiplex Testing: CDRH Guidance Provokes Array Of Industry Comments
Multiplex Testing: CDRH Guidance Provokes Array Of Industry Comments
Exact Data On PreGen Plus Colorectal Cancer Genomics Test Due In 2003
Advertisement
UsernamePublicRestriction

Register

MT018870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel